Great discrepancies between European, Dutch and Belgian criteria for the use of statins in the prevention of primary cardiovascular disease in family practice

• Published in: Nederlands tijdschrift voor geneeskunde Vol. 145; no. 8; p. 361
• Main Authors: Van Diest, E, Stoffelen, E, Wydooghe, L, Van Duppen, D, Seuntjens, L, Van der Stuyft, P
• Format: Journal Article
• Language: Dutch
• Published: Netherlands 24.02.2001
• Subjects: Aged; Belgium; Cardiovascular Diseases - prevention & control; Cost-Benefit Analysis; Drug Prescriptions - standards; Drug Prescriptions - statistics & numerical data; Europe; Family Practice - statistics & numerical data; Female; Humans; Hyperlipidemias - drug therapy; Hypolipidemic Agents - economics; Hypolipidemic Agents - standards; Hypolipidemic Agents - therapeutic use; Male; Middle Aged; Netherlands; Practice Guidelines as Topic - standards; Belgium; Netherlands; Europe
• ISSN: 0028-2162

To determine the differences in prescribing advice for statines in primary cardiovascular prevention, applying different protocols, in a first-line setting. In February-March 2000, at the general practice 'Medicine for the People' in Deurne-Antwerp, Belgium, all contacts with patients known with at least one cardiovascular risk factor and no signs of cardiovascular disease were included in the study. The absolute risk of developing cardiovascular disease in the next 10 years was calculated per patient according to the protocols of the 'European Society of Cardiology' (ESC) and the Dutch College of General Practitioners (NHG) and it was determined whether these protocols advised prescription of statines. It was also determined if the Belgian criteria for repayment of statines, developed by the Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV) were met. The study group comprised 143 patients with a mean age of 66 years, of which 51 (36%) were men. According to the RIZIV criteria 75 (52%) patients of these 143 were eligible for the repayment of statines. The NHG protocol advised to prescribe statines for 4 (3%) patients and the ESC protocol for 69 (48%) patients. Of the 75 patients who were considered for repayment, 34 (45%) according to the ESC protocol and 74 (99%) according to the NHG protocol did not need statines. Also, in the whole study population, 28 (20%) patients needed statines according to ESC and 3 (2%) patients according to NHG, but they could not get repayment for statines according to the RIZIV. The ESC protocol estimated the risk per patient on average 8.5% (95% confidence interval: 7.1-9.8; p < 0.0001) higher than the NHG protocol. The NHG protocol estimated the risk significantly and markedly lower than the European protocol, although they are both based on the same Framingham data. There also existed a weak concordance between both protocols. The RIZIV criteria were not 'evidence-based'. They incited to an irrational and wasting prescribing behaviour. There is a need for an integrated guideline for primary cardiovascular prevention and for the adjustment of the RIZIV criteria.